SEMA6B induces macrophage-mediated inflammation and hepatocyte apoptosis in hepatitis B virus-related acute-on-chronic liver failure

Hui Yang, Qun Cai, Jiaojiao Xin, Xi Liang, Hozeifa Mohamed Hassan, Jiaxian Chen, Lulu He, Suwan Sun, Beibei Guo, Shiwen Ma, Bingqi Li, Xiaofei Zeng, Meiqian Hu, Peng Li, Jinjin Luo, Wen Hu, Heng Yao, Xingping Zhou, Yuheng Kong, Qiuzhi Wang, Xin Chen, Jing Jiang, Dongyan Shi, ­Jun Li­Theranostics 2024 · DOI

TL;DR

This study identifies Semaphorin-6B (SEMA6B) as a crucial driver of inflammation and hepatocyte apoptosis in Hepatitis B Virus-related Acute-on-Chronic Liver Failure (HBV-ACLF), a severe condition with high mortality. SEMA6B not only serves as a promising diagnostic biomarker but also represents a potential therapeutic target for this devastating disease.

What Problem Does This Paper Address?

Acute-on-Chronic Liver Failure (ACLF) is a life-threatening syndrome characterized by rapid deterioration of liver function and often multiorgan failure, leading to very high short-term mortality rates, particularly in cases related to Hepatitis B Virus (HBV). Understanding the underlying mechanisms of HBV-ACLF is critical for developing effective diagnostic tools and treatments. While previous research has hinted at the involvement of immune dysregulation, the specific molecular players and their roles in disease progression have remained unclear. This paper aims to pinpoint key molecules and elucidate their mechanisms in HBV-ACLF pathogenesis, focusing on SEMA6B, which was previously identified as a potential biomarker.

Methods

The researchers employed a multi-pronged approach to investigate SEMA6B's role in HBV-ACLF. They began with a large-scale transcriptome analysis of peripheral blood mononuclear cells (PBMCs) from 321 patients across different stages of liver disease (HBV-ACLF, liver cirrhosis, chronic hepatitis B) and healthy controls. This allowed them to identify differentially expressed genes, with SEMA6B standing out. To validate SEMA6B's diagnostic potential, they used Receiver Operating Characteristic (ROC) curve analysis.

To understand the mechanisms of SEMA6B, they moved to in vitro studies using cell lines (macrophages and hepatocytes) where they manipulated SEMA6B expression (overexpression and knockdown). They also conducted in vivo experiments using SEMA6B knockout mice and mice treated with synthetic SEMA6B siRNA, exposing them to an LPS/D-gal induced liver failure model. Various techniques were used to assess inflammation (cytokine analysis, immunohistochemistry), apoptosis (TUNEL assay), cell proliferation (CCK8 assay), and cell cycle progression (flow cytometry).

Datasets

The study utilized data from a prospective multicenter cohort of 321 patients.

  • Sequencing Cohort: 84 subjects (HBV-ACLF, n=50; LC, n=10; CHB, n=10; NC, n=14) underwent mRNA sequencing of PBMCs.
  • External Validation Cohort: Data from an additional 92 HBV-ACLF patients, 50 LC, 50 CHB, and 45 NC patients were used for validation via qRT-PCR and immunohistochemistry.
  • Publicly Available Data: RNA-seq data from healthy donors and single-cell RNA-seq data from healthy liver tissues were also analyzed to identify cell types expressing SEMA6B.

No new benchmark datasets were introduced; the study relied on existing patient cohorts and publicly available data.

Key Insights and Ideas

  • SEMA6B as a Master Regulator: The study strongly suggests SEMA6B isn't just a marker but an active participant in driving HBV-ACLF. Its overexpression appears to directly trigger harmful processes.
  • Dual Role in Inflammation and Apoptosis: SEMA6B seems to orchestrate both the inflammatory cascade and programmed cell death in hepatocytes, the two key pathological features of severe liver injury.
  • Macrophage-Hepatocyte Axis: The findings highlight a critical interaction where SEMA6B in macrophages fuels systemic inflammation, which in turn, coupled with SEMA6B's direct effects on hepatocytes, leads to their apoptosis.
  • Therapeutic Potential: The successful rescue of mice with liver failure upon SEMA6B knockout or siRNA treatment points towards SEMA6B as a viable therapeutic target.

Key Results

  • Diagnostic Power: SEMA6B levels were significantly elevated in HBV-ACLF patients, especially non-survivors. ROC analysis showed high diagnostic accuracy for SEMA6B in distinguishing HBV-ACLF from other liver conditions (AUROC = 0.9788 in the sequencing cohort, 0.9026 in the external validation cohort).
  • Cellular Localization: SEMA6B was found to be highly expressed in hepatocytes and macrophages within the liver tissue of HBV-ACLF patients.
  • Inflammation Activation: Overexpression of SEMA6B in macrophages led to increased production of pro-inflammatory cytokines (e.g., IL-6, TNF-α) and chemokines (e.g., CCL2).
  • Hepatocyte Apoptosis Induction: SEMA6B overexpression in hepatocytes inhibited proliferation and induced apoptosis.
  • Protective Effects of SEMA6B Deficiency: In mice, SEMA6B knockout significantly improved liver function, reduced hepatic necrosis, and prolonged survival following liver injury induction.
  • Therapeutic Efficacy: Treatment with synthetic SEMA6B siRNA in mice with liver failure also improved liver function, reduced inflammation, and mitigated hepatocyte apoptosis.

Limitations and Future Work

The authors acknowledge several limitations:

  • Animal Model Discrepancy: The use of an LPS/D-gal-induced acute liver failure (ALF) mouse model, while useful, may not perfectly recapitulate all aspects of HBV-ACLF, as there are clinical differences between these conditions.
  • Genetic Knockout Specificity: The study used SEMA6B embryonic knockout mice due to the limited availability of macrophage- and hepatocyte-specific knockout models. This means the precise molecular mechanisms within specific cell types in ACLF cannot be definitively verified.
  • Etiology Specificity: The study focused on HBV-ACLF, limiting the generalizability of findings to ACLF patients with other underlying causes.

Future work should focus on validating these findings in larger, multicenter cohorts with diverse etiologies of ACLF. Further research into the precise molecular mechanisms by which SEMA6B influences inflammation and apoptosis in ACLF is also warranted. The therapeutic potential of targeting SEMA6B, as suggested by the siRNA studies, warrants further investigation for clinical application.

Summary updated

Abstract

<b>Rationale:</b> Patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) have a high short-term mortality rate. Semaphorin-6B (SEMA6B) plays a crucial role in the pathogenesis of HBV-ACLF, but its molecular basis remains unclear. This study aimed to elucidate the mechanisms of SEMA6B in HBV-ACLF progression. <b>Methods:</b> A total of 321 subjects with HBV-ACLF, liver cirrhosis (LC), chronic hepatitis B (CHB), and normal controls (NC) from a prospective multicenter cohort were studied. 84 subjects (HBV-ACLF, n = 50; LC, n = 10; CHB, n = 10; NC, n = 14) among them underwent mRNA sequencing using peripheral blood mononuclear cells (PBMCs) to clarify the mechanisms of SEMA6B in HBV-ACLF. These mechanisms were validated through in vitro studies with hepatocytes and macrophages, as well as in vivo using SEMA6B knockout mice and mice treated with synthetic SEMA6B siRNA. <b>Results:</b> Transcriptome analysis of PBMCs showed that SEMA6B was among the most differentially expressed genes when comparing patients with HBV-ACLF to those with LC, CHB, or NC. ROC analysis demonstrated the reliable diagnostic value of SEMA6B for HBV-ACLF in both the sequencing cohort and an external validation cohort (AUROC = 0.9788 and 0.9026, respectively). SEMA6B levels were significantly higher in the HBV-ACLF patients, especially in non-survivors, with high expression mainly observed in macrophages and hepatocytes in liver tissue. Genes significantly associated with highly expressed SEMA6B were enriched in inflammation and apoptosis pathways in HBV-ACLF non-survivors. Overexpression of SEMA6B in macrophages activated systemic inflammatory responses, while its overexpression in hepatocytes inhibited proliferation through G0/G1 cell cycle arrest and induced apoptosis. Knocking out SEMA6B rescued mice with liver failure by improving liver functions, reducing inflammatory responses, and decreasing hepatocyte apoptosis. Transcriptome analysis of liver tissue showed that SEMA6B knockout significantly ameliorated the liver failure signature, significantly downregulating inflammation-related pathways. Importantly, therapeutic delivery of synthetic SEMA6B siRNA also improved liver function, and reduced both inflammation and hepatocyte apoptosis in mice with liver failure. <b>Conclusion:</b> SEMA6B, a potential diagnostic biomarker for HBV-ACLF, exacerbates liver failure through macrophage-mediated systemic inflammation and hepatocyte apoptosis. These findings highlight SEMA6B as a promising early treatment target for HBV-ACLF patients.
BibTeX
@inproceedings{yang2024sema,
  author = {Hui Yang and Qun Cai and Jiaojiao Xin and Xi Liang and Hozeifa Mohamed Hassan and Jiaxian Chen and Lulu He and Suwan Sun and Beibei Guo and Shiwen Ma and Bingqi Li and Xiaofei Zeng and Meiqian Hu and Peng Li and Jinjin Luo and Wen Hu and Heng Yao and Xingping Zhou and Yuheng Kong and Qiuzhi Wang and Xin Chen and Jing Jiang and Dongyan Shi and ­Jun Li­},
  title = {{SEMA6B induces macrophage-mediated inflammation and hepatocyte apoptosis in hepatitis B virus-related acute-on-chronic liver failure}},
  booktitle = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.97007},
}
Figure